RMD

ANALYST NOTE: RMD (ResMed Inc.) Date: 2026-06-13 Analyst: StoryStocks-Native Equity Analyst

1. Structural Readiness

Current State: INVALIDATED

• Conservative Entry: None (Setup is invalid).
• Aggressive Entry: None (The "forming" entry of $272 is no longer relevant as the structure has broken).
• Breakout Level: $293.81 (This level is now a resistance target for a future recovery, not a current trigger).

Classification: The coil is INVALIDATED.

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Exposure: None named at this date.

As of 2026-06-13, there is no named macro or secular thesis driving this specific trade. This is a tactical, setup-led name. The investment case must be judged strictly on the quality of the technical structure (which is currently broken) and the underlying business fundamentals. No external narrative or "story" should be invented to justify a long position in a technically invalidated setup. The conviction must derive from the business's ability to recover the lost ground, not from a pre-existing thematic tailwind.

3. The Business

Company Overview: ResMed Inc. is a global leader in the development, manufacturing, distribution, and marketing of medical devices and cloud-based software applications. The company focuses on diagnosing, treating, and managing respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), and neuromuscular diseases.

Business Model & Operations (Evidence as of 2026-06-13):

• Revenue Drivers: The core business is the "Sleep and Breathing Health" segment. In the three months ended March 31, 2026, this segment generated $1,260.5 million in net revenue, an 11% increase year-over-year.
• Product Mix: The "masks and other" category saw a 15% increase to $524.8 million in the same period, up from $454.4 million in Q1 2025.
• Innovation & R&D: The company invested $94.3 million in R&D during Q1 2026, representing 6.6% of net revenues. This capital is directed toward new products like the AirSense 11, which features a touch screen, new algorithms for new patients, and over-the-air update capabilities.
• Strategic Acquisitions:
• Noctrix Health: Management expects to close the transaction for Noctrix Health on or around June 1, 2026 (just prior to this date). Noctrix has an annual revenue run rate of approximately $24 million and is expected to reduce non-GAAP EPS by approximately $0.02 in Q4 fiscal 2026.
• VirtuOx: Acquired in May 2025, this software-enabled independent diagnostic testing facility (IDTF) strengthens the company's end-to-end capabilities in home-based diagnostics and remote monitoring.
• Market Context: Management cites a large population-based study in the UK (published in *Thorax*) linking obstructive sleep apnea (OSA) to increased risks of dementia, and notes that RLS impacts 17 million people in the U.S. alone. The company's "AirTouch N30i" mask has shown 6% higher 90-day compliance compared to silicone equivalents in real-world data.

4. Archetype and Conviction

Archetype: Quality Compounder Fit Analysis: ResMed fits the "Quality Compounder" archetype due to its consistent revenue growth (11% YoY in Sleep/Breathing), expanding gross margins (62.2% in Q1 2026 vs. 59.3% in Q1 2025), and heavy reinvestment in R&D (6.6% of revenue). The company is successfully transitioning from a pure hardware play to a "connected care" model via cloud software and acquisitions like VirtuOx.

Conviction Stack:

• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: High. The financials (E13-E16) and strategic updates (E1-E4, E18) are robust, showing clear execution on margin expansion and product innovation.
• Setup Readiness: None. The setup is invalidated.
• Rerating Potential: Dependent on the successful integration of Noctrix and the market's reaction to the margin expansion, but currently obscured by the technical breakdown.

ATR Context:

5. Invalidating/Strengthening Factors & Gaps

What Would Invalidate the Case Further:

• A continued decline below the current price of $188.63 without a retest of the $245.21 level.
• Management guidance revisions indicating that the Noctrix acquisition will have a more significant negative impact on EPS than the projected $0.02.
• Gross margins failing to hold within the 62-63% range for the full fiscal year 2026.

What Would Strengthen the Case:

• Confirmation that the Noctrix transaction closes on schedule (June 1, 2026) and the $24M revenue run rate is realized without integration friction.
• Continued margin expansion driven by the "manufacturing and logistics efficiencies" cited in Q1 2026.

Gaps in Evidence:

• Missing Evidence: There is no specific evidence regarding the *current* order book or backlog as of June 13, 2026, beyond the Q1 2026 results.
• Missing Evidence: No specific data on the *post-acquisition* integration timeline for Noctrix beyond the closing date expectation.
• Missing Evidence: No specific valuation multiples (P/E, EV/EBITDA) are provided in the evidence block to contextualize the $188.63 price level relative to historical norms.

PRIVATE ANALYST CALL

Judgment: Sell Confidence: high Key risks: No named secular thesis to support a long-term hold; technical structure requires a retest of $245.21 to become viable; potential EPS drag from Noctrix integration. Sizing hint: Position size should be zero; capital preservation is the priority until structure is restored. Expected path: Management expects Noctrix to close June 1, 2026, and margins to hold 62-63%; however, the technical breakdown suggests the market is pricing in a near-term negative catalyst or loss of momentum. Expected horizon: Indefinite; the setup is currently dead and requires a new formation cycle. Failure mode to watch: A close below $188.63 confirming a deeper structural breakdown and potential trend change to the downside.